Company
Headquarters: Andover, MA, United States
Employees: 148
CEO: Dr. Waleed H. Hassanein
$4.19 Billion
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Abbott | $216.15 B |
| Boston Scientific Corporation | $140.40 B |
| Stryker | $133.15 B |
| Medtronic | $123.20 B |
| Edwards Lifesciences Corporation | $50.10 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | $566.4 M |
| EBITDA | $131.6 M |
| Gross Profit TTM | $341.4 M |
| Profit Margin | 16.20% |
| Operating Margin | 16.20% |
| Quarterly Revenue Growth | 32.20% |
TransMedics Group, Inc. has the following listings and related stock indices.
Stock: NASDAQ: TMDX